Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

About this update from Rani Therapeutics Holdings, Inc.

SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing Phase 1 study of RT-114, an orally administered RaniPill® Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd. ("ProGen"). The initial data demonstrated that oral RT-114 achieved systemic exposure exceeding that of matched subcutaneous administration, with a safety and tolerability profile consistent with the GLP-1/GLP-2 agonist class of therapeutics. "The safety and bioavailability findings reported today exceeded our expectations and represent an important milestone for the RaniPill® platform," said Talat Imran, Chief Executive Officer of Rani. "We have previously demonstrated that the RaniPill® can orally deliver a broad range of biologics across multiple therapeutic areas. With RT-114, we have now extended that capability into obesity and metabolic disease while achieving systemic exposure well above that of the matched subcutaneous dose. At a time when many oral biologic delivery technologies continue to produce only a small fraction of subcutaneous exposure, these data reinforce the unique potential of the RaniPill® platform." Phase 1a Study Design and Results The ongoing Phase 1a study is evaluating the safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics of RT-114 relative to subcutaneous PG-102. In the single-dose, open-label Phase 1a portion of the study, 30 healthy volunteers were randomized to receive an identical 12 mg dose of PG-102, delivered either orally via RT-114 or by subcutaneous injection. Key Findings:

View stock analysis, news, and events for Rani Therapeutics Holdings, Inc.